Contact Us

ODISEI

Organoid-based Discovery platform for Innovative Screening, Evaluation and Identification

Organoid-based drug efficacy and toxicity evaluation solution

ODISEI ONC

Oncology

ODISEI PET

Companion Animals

ODISEI VIR

Infectious Diseases

ODISEI NEP

Renal Diseases

ODISEIGUT

Nutraceuticals

ODISEI CNS

Brain Diseases

ODISEI SKIN

Cosmetics

ODISEI HEP

Liver Diseases

ODISEI Spatial

Spatial Biology

Overview

ODISEI Solution precisely predicts the efficacy of rapidly evolving new materials
Discrepancies between animal testing and human results
The rise of animal ethics and the spread of alternative methods to animal testing
Astronomical costs involved &  Low success rates
Challenges in evaluating new modality drugs
Providing the optimal evaluation solution to accurately assess advanced pharmaceuticals and new materials without animal testing, enhancing the efficiency of drug development

Advantages of Organoid Model

Experience more precise, easier, faster, and reliable drug efficacy evaluation ODISEI Solutions for your successful drug discovery.
Type Similarity with human organs Physiological complexity Time for Establishment Success
rate Mass
production Ethical
issue
3D Organoid High Relatively complex Weeks High Possible No
2D Cells (PDC) Low Simple Days High Possible No
PDX Model (PDX) High Complex Months Low Impossible Yes

Strategies: Basic Research

  • Connecting genotypes to specific phenotypes
  • Cancer initiation and progression
  • Clonal evolution
  • Cancer stem cell characterization
  • Mechanism of drug response and resistance

Utilization Strategy for Each Stage of New Drug Development

Target Section
1. New target excavation and verification
Lead Finding,
Prioritization Optimization
2. New drug screening
3. Drug efficacy Evaluate and optimize
Phase I
4. Clinical trial Prediction of success rate
Phase II
Phase III
5. Clinical trial protocol development
6. Treatment prediction marker development

Organoid Establishment and Banking

Over 20 diverse organoids, including TME (Tumor Microenvironment) , enabling cutting-edge trends like Neoantigen and Immunotherapy applications
  • Skin & Hair
  • Cerebral
  • Midbrain
  • Lacrimal Gland
  • Salivary Gland
  • Adenoid
  • Tonsil
  • Lung
  • Heart
  • Liver
  • Stomach
  • Kidney
  • Intestine
  • Prostate Cancer
  • Hepatocellular Carcinoma
  • Breast Cancer
  • Pancreatic Cancer
  • Renal Cell Carcinoma
  • Endometrial Cancer
  • Head & Neck Cancer
  • Non-Small Cell Lung Cancer
  • Cholangiocarcinoma
  • Gastric Cancer
  • Colorectal Cancer
  • Ovarian Cancer

Available pre-clinical research

  • Donor-matched immune microenvironment
  • Various patient-derived organoid lineups
  • High-resolution data
    (HCS, FACS, NGS, scRNAseq, multiflex IHC)
  • Fully customized service

Available clinical data

  • Basic clinical data
  • Drug sensitivity prediction
  • Patient follow-up data
  • Clinical bioinformatics
    (NGS, RNAseq, Spatial biology)

Applications

Find out how we can be your partner in providing ethical choices and exceptional results

Client

Therapeutic Approaches

  • Antibodies
  • Anti-Cancer Drugs
  • Vaccines
  • Small Molecules
  • Peptides
  • Nucleosides
  • Microbiome
  • Virus
  • Cosmetic Compounds
  • Proinflammatory-Cytokines
  • Proinflammatory-Chemokines

Disease Modeling

  • Oncology Virus
  • Oncology Skin
  • Oncology Gut
  • Cytotoxic T Cells
  • Macrophages
  • DCs
  • Tregs
  • NKs
  • CAFs
  • Skin
  • Intestinal
  • Liver
  • Kidney
  • Cardiac
  • Lung
  • Stomach
  • Brain

Read-outs

  • Morphology
  • Cell viability
  • Cell type composition
  • Gene expression
  • Mutation profiling
  • Immune cell profiling
  • Pathway analysis
  • Cell to cell interaction
  • Metabolism

Analysis

  • High-content Screening
  • Cell Viability
  • Fluorescence-sorting
  • Fluorescence-activated Cell Sorting
  • Confocal Microscopy
  • Immunohistochemistry
  • Immunofluorescence
  • Phenocycler-fusion
  • (Multiplex-IHC)
  • -CODEX, OPAL
  • Bulk-RNAseq
  • Single Cell RNAseq
  • Whole Genome Sequencing
  • MS/MS

Report

ODISEI ONC

Precision oncology solution replicating patient tumors and immune microenvironments for anti-cancer and immunotherapy evaluation

High-Fidelity Preclinical Models

Oncology utilizes 3D patient-derived organoids (PDOs) cultured directly from tumor biopsies.
These models preserve the original tumor’s genetic and phenotypic characteristics, providing a more clinically relevant system than traditional 2D cell lines or animal models.

Extensive Organoid Biobanking

A comprehensive biobank of PDOs, derived from a wide range of cancer types, forms an expansive repository that supports robust screening efforts.
This resource enables the identification of drug candidates across diverse tumor profiles and informs strategic decision-making throughout the R&D pipeline.

ODISEI-ONC : Immuno-Oncology Drug Evaluation Platform Using Tumor Organoids

Features

Enhance clinical predictive accuracy by developing advanced models that more accurately recapitulate the Tumor Microenvironment (TME)

Immune-Microenvironment with Cytoxic T cells

Immune checkpoint determine whether cancer cells are killed after TCR-MHC binding
stablishment of an immune checkpoint blockade evaluation platform utilizing cancer organoids and autologous T cells

Tumor-Infiltrating Lymphocyte (TIL)

Regulatory T cell (Treg)

Macrophage

Cancer Associate Fibroblast (CAF)

Validation Complete for caner organoid

  • Clinical information
  • Drug sensitivity test
  • Genetic mutation (WES analysis)
  • Specific cancer marker expression
    (Immunohistochemistry, Multiflex)

WES analysis in pancreatic cancer organoid

Drug sensitivity test in pancreatic cancer organoid

ODISEI GUT

Intestinal organoid-based solution enabling disease modeling and drug response prediction with organ-level functional fidelity

Generation of human intestinal organoid (hIO)

iPSC-derived intestinal organoids

iPSC-derived intestinal organoids are 3D models that replicate intestinal tissue using induced pluripotent stem cells (iPSCs), playing a key role in intestinal development and disease research. These organoids are generated by differentiating iPSCs into intestinal progenitor cells and cultivating them in a suitable extracellular matrix to form 3D structures. The organoids mature into structures with key intestinal layers and functions, which can be assessed through their absorption capacity, bacterial adhesion ability, and drug responses, mimicking real intestinal tissue.

Tissue-derived intestinal organoids

Tissue-derived intestinal organoids are 3D models created using intestinal cells directly isolated from tissue, providing a valuable tool for studying intestinal development, function, and diseases. These organoids are typically generated by culturing intestinal epithelial cells derived from intestinal tissue. Under specialized culture conditions, the cells form 3D structures that closely mimic the natural architecture and function of the intestine. By providing extracellular matrix (ECM) components and growth factors, the cells spontaneously organize into the key layers and morphology of the intestine, maintaining a microenvironment similar to that of the native tissue. These organoids are widely used for modeling intestinal diseases, drug testing, and studying both physiological and pathological conditions of the intestine.

Cellular and structural similarity

The small intestine is a crucial organ responsible for nutrient absorption, consisting of four layers: the mucosa, submucosa, muscularis propria, and serosa. Inside the small intestine, villi maximize nutrient absorption, while crypts serve as regions where intestinal epithelial cells proliferate. Additionally, microvilli further expand the surface area for absorption.

The major cell types include enterocytes responsible for nutrient uptake, goblet cells that secrete mucus, Paneth cells that produce antimicrobial peptides, enteroendocrine cells that release hormones, and intestinal stem cells that regenerate the intestinal epithelium.

Intestinal organoids have a structure and cellular composition similar to human intestinal tissue and mimic the functions of the small intestine.

In our intestinal organoids, key markers for function and cell status have been identified, including Ki67, associated with cell proliferation; E-cadherin (Ecad), which maintains cell adhesion; OLFM4, a marker for intestinal stem cells; MUC13, involved in mucus secretion; and KRT20, indicative of mature intestinal epithelial cell differentiation.

Ki67 – Strongly expressed in proliferating cells within the crypts, indicating active cell proliferation

E-cadherin – Essential for maintaining adhesion between epithelial cells, ensuring structural integrity

OLFM4 – A key marker of intestinal stem cells, specifically expressed in the crypt region

MUC13 – Expressed in goblet cells and some enterocytes, contributing to the protection of the intestinal

KRT20 – Expressed in mature enterocytes, serving as an indicator of epithelial cell differentiation

Intestinal Disease & Function Models

LGS (Leaky Gut Syndrome) Model
Development of leaky gut model causing diverse intestinal disease and treatment probiotics product to recovery.
As the tight junction loosens, the permeability of the intestinal lining increases
IBD (Inflammatory Bowel Disease) Model
Induction of Inflammatory Bowel Disease (IBD) model using Pro-Inflammatory cytokines and assessment of therapeutic efficacy.
Drug Absorption and Permeability Evaluation Method
Results similar to human tests were obtained when evaluating drug metabolism and permeability in the intestinal epithelial model.
Analysis of Metabolites After Drug Treatment
Microbiome & Probiotics
Discover Probiotic Potential with Our Gut-like hIESC Model Unlock the next generation of probiotic research. Leverage our highly physiologically relevant hIESC-based intestinal model engineered to closely mimic
The real difference lies in adhesion
(Only select probiotics truly stay and act in the gut)

ODISEI SKIN

Human skin organoid solution recreating cellular structures and hair follicles for high-precision efficacy testing

Generation of hair bearing skin organoid

We provide hair-bearing mature skin organoids developed through our differentiated technology based on hPSC-derived human skin organoids.

Cellular and structural similarity

Our skin organoids can be observed in a mature form with the epidermal layer, dermal layer, and subcutaneous tissue that appear in actual skin structure. It is also composed of various cells such as fibroblasts, melanocytes, hair follicle-related cells, and adipocytes.
Structural characteristics of skin organoids

Skin Structure

  • Expression Markers

Epidermis

  • KRT5Basal Layer
  • KRT10Spinous Layer
  • KRT15Peridermal
  • TFAP2AIntermediate Layer

Dermis

  • VimentinFibroblast Intermediate Filament
  • PDFGFRαMesenchyme- Associated Cell
  • COL1Collagen
  • EDARHair Germ
  • SOX2Hair Follicle

Hypodermis

  • LipidtoxAdipocytes
Advanced skin organoid manufacturing technology
Previous method
Our skin organoids can be observed in a structurally mature form and are capable of uniformly forming a higher number of hair follicles. Compared to traditional artificial skin models and 2D cell lines, our skin organoids exhibit superior performance in replicating the complexity and functionality of human skin.

Hypodermis

  • KRT5
  • KRT17
  • EDAR
  • SOX2

Skin structure

  • Basal Layer [Epidermis]
  • Cornified envelope [Epidermis]
  • Hair Gem [Dermis]
  • Dermal papilla cell [Dermis]
Advanced method
Evaluation of drugs for hair formation effectiveness
Structural characteristics of  skin organoids
In order to discover drugs that help in the formation of hair, active substances were treated at the time when hair bulbs in skin organoids were formed, and drugs that increased hair follicle formation compared to the control group were selected.
When treated with an effective drug, an increase in the number of hair follicles was obtained, and additional research on mechanisms related to hair follicle formation was conducted.
Hair formation efficacy test using skin organoids
Hair loss model production and effectiveness evaluation
To create a hair loss model, we treated skin organoids with hair with the male hormone DHT to create a hair loss model. It was confirmed that hair loss was suppressed by co-administration with Minoxidil, a known hair loss treatment, and was used to discover effective candidates.

ODISEI Spatial

Spatial biology solution modeling tissue architecture and cell interactions for efficacy analysis and biomarker discovery

Phenocycler(CODEX)

CODEX was developed to overcome the limitations of existing IHC.

Multiplex-IHC is an experimental method that can confirm the expression of more than 100 biomarkers on one tissue slide.

It is possible to check the expression of various biomarkers on a single tissue slide and conduct comprehensive research on cell composition, cell function and state, and cell-cell interaction.

CODEX analysis is performed using DNA barcoding and uses antibodies conjugated to unique oligonucleotide sequences. By using a target specific barcode called dye-labelled reporter, it is possible to stain more than 100 biomarkers by repeating the labeling cycle by dyeing three colors of fluorescence in one cycle.

Our Core Values

  • Staining more than 100 biomarkers on tissue slides 1 chapter.
  • Mapping of Millions of Cells Through Diverse Panel Combinations.
  • Single cell resolution analysis.
  • Cell phenotyping using marker staining combinations.
  • Cellular Neighborhood Analysis Utilizing Spatial Information of Cells.

A new standard for Immuno-oncology research has arrived

Whether you’re looking to unlock the intricacies of the tumor microenvironment(TME), shed light on checkpoint therapy mechanisms, or drive breakthroughs in immunotherapy research, the PhenoCodeTM Discovery IO60 Human Protein Panel is a comprehensive, fast and scalable solution for ultrhigh-plex immune phenotyping-setting a new standard for immuno-oncology(IO) research.

New panel (IO60) Open

Advantage of IO60
  • Expanded panel enables deeper profiling of immune-tumor interactions.
  • Improved resolution in identifying rare immune subsets and tumor heterogeneity.
  • Enhanced capability for co-expression and spatial marker mapping.
  • More markers, more insight—accelerate biomarker discovery and therapeutic evaluation.

Immune cell type core

  • 1. CD68
  • 2. CD4
  • 3. CD44
  • 4. CD45RO
  • 5. CD45
  • 6. CD11c
  • 7. CD8
  • 8. HLA-A
  • 9. HLA-DR
  • 10. CD14
  • 11. CD20
  • 12. CD3e
  • 13. CD56

Immune activation

  • 1. IFNG
  • 2. IDO1
  • 3. PD-1
  • 4. ICOS
  • 5. PD-L1
  • 6. LAG-3
  • 7. VISTA

Tissue architecture

  • 1. CD31
  • 2. E-cadherin
  • 3. SMA
  • 4. Vimentin
  • 5. CD34
  • 6. Beta-actin
  • 7. Podoplanin
  • 8. Collagen IV
  • 9. Caveolin
  • 10. B-catenin1

Lymphocyte profiling

  • 1. CD107
  • 2. CD57
  • 3. FOXP3
  • 4. CD21
  • 5. CD38
  • 6. Granzyme B
  • 7. TOX
  • 8. TCF-1
  • 9. CD79a
  • 10. CD39

Myeloid profiling

  • 1. iNOS
  • 2. CD66
  • 3. MPO
  • 4. CD163
  • 5. CD11b
  • 6. CD206
  • 7. CD209

Proliferation

  • 1. Histone H3 Phospho(Ser28)
  • 2. PCNA
  • 3. Ki67

Tumor-specific marker

  • 1. Keratin 14
  • 2. SOX2
  • 3. Pan-CK
  • 4. Keratin 8/18
  • 5. ER
  • 6. Bcl-2
  • 7. EpCAM
  • 8. GP100
  • 9. TP63
  • 10. Keratin 5
The published paper using our platform
Read out
31markers (charged slide)
To identify the mechanism of a new target, acquire spatial information by simultaneously staining 31 marker in PDOX tissue.
Teratoma formation analysis
Simultaneous staining of 31 markers in tumor tissue
Identification of treatmentmechanism through spatial analysis of cell types
Identifying immunological mechanisms underlying the efficacy of anticancer immunotherapy and discovering biomarker candidates through theapplication of spatial biology

Toward a Sustainable Future
with ORGANOIDSCIENCES

Join ORGANOIDSCIENCES in leading groundbreaking organoid research and the advancement of next-generation cell therapies.
Be part of the journey of biomedical innovation that is shaping the future of healthcare.

Technical Inquiry

bd@organoidrx.com

PR/Marketing inquiry

pr@organoidrx.com

Recruitment inquiry

hr.admin@organoidrx.com

General Inquiry

info@organoidrx.com